Regeneron stock skyrocketed Thursday on news that an 8-milligram dose of an eye drug successfully treated patients with diabetic macular edema and wet age-related macular degeneration in two

pivotal trials. Regeneron Pharmaceuticals (REGN) announced that the studies showed that 8-mg 12- and 16-week dosing regimens of the generic form of its Eylea drug, called aflibercept,

"achieved non-inferiority in vision gains…